Media Release
SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, will participate in The JMP Securities Hematology and Oncology Summit, a virtual investor event to be held from December 6-7, 2022.
Presentation Details:
Date: Wednesday, 7 December 2022
Time: 11:20am EST
Mr. Voigt will be available for virtual one-on-one meetings during the conference. A live webcast of his presentation will be available here and after the meeting under the Events page within the Investors & Media section of Immutep’s website.
About Immutep
Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Immutep’s lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep’s large pharmaceutical partners.
Further information can be found on the Company’s website www.immutep.com or by contacting:
Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com
U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (917) 679 9282; tim@lifesciadvisors.com
Co-CEO of The Permanente Federation and leader of multiple Permanente Medical Groups at Kaiser Permanente,…
RESEARCH TRIANGLE PARK, N.C., June 12, 2025 /PRNewswire/ -- Dignify Therapeutics (Dignify), a pharmaceutical and medical…
CHICAGO, June 12, 2025 /PRNewswire/ -- Workplace miscommunication costs businesses an estimated $1.2 trillion annually and…
Step aboard the world's largest civilian-run hospital ships and witness stories of compassion, courage, and…
JOHNSON CITY, Tenn., June 12, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central…
ROSWELL, Ga., June 12, 2025 /PRNewswire/ -- Buds Technology, a leading innovator in healthcare solutions, has…